Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citalopram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Citalopram SCHEMBL13235283 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL29494157 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| (R)-Citalopram SCHEMBL29414626 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Escitalopram SCHEMBL29358316 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL3858802 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Escitalopram SCHEMBL34948 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Escitalopram SCHEMBL522164 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL1118 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL21820669 | 0.99 | SLC6A4 (0.98) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL1286979 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 38366 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4746863-A1 | ENDOXIFEN COMPOSITIONS AND METHODS OF USE THEREOF AND SYNTHESIS THEREOF | Atossa Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-110609095-B | Method for determining citalopram or a salt thereof and related substances in a formulation thereof | 苏州科伦药物研究有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739303-A2 | MDMA ENANTIOMER COMPOSITIONS AND METHODS FOR MODULATING AGGRESSION RESPONSE | EmpathBio, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-1990004387-A2 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-03 | — | — | WO | claimed |
| EP-0347066-A1 | New enantiomers and their isolation | H. LUNDBECK A/S (DK) | 1989-12-20 | — | — | EP | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |
| EP-0303961-A2 | Novel antidepressants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-02-22 | — | — | EP | claimed |
| EP-0293714-A1 | Combinations of compounds with anti-depressive activity | Troponwerke GmbH & Co. KG (DE) | 1988-12-07 | — | — | EP | claimed |
| EP-0171943-B1 | NOVEL INTERMEDIATE AND METHOD FOR ITS PREPARATION | H. LUNDBECK A/S (DK) | 1988-11-17 | — | — | EP | claimed |
| US-4650884-A | 4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (racemic citalopram diol) as intermediate to citalopram | H. LUNDBECK A/S (DK) | 1987-03-17 | — | — | US | claimed |
| EP-0171943-A1 | Novel intermediate and method for its preparation | H. LUNDBECK A/S (DK) | 1986-02-19 | — | — | EP | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| US-4136193-A | ANTI-DEPRESSIVE SUBSTITUTED 1-DIMETHYLAMINOPROPYL-1-PHENYL PHTHALANS | KEFALAS A/S (DK) | 1979-01-23 | — | — | US | claimed |